Physician profile
Shannon Andersen-Thomas
NPI 1205820636
$1,822.02
in general payments reported to CMS, 2019-2025
29 companies · $405 in 2025
The $405 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $122 · 2021: $39.04 · 2022: $84.39 · 2023: $408 · 2024: $514 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $326.78 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $190.37 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $165.00 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $134.74 | 2023-2024 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $116.81 | 2022-2025 | |
| Avion Pharmaceuticals | $113.45 | 2019-2023 | Balcoltra |
| Shield Therapeutics INC | $94.00 | 2024-2025 | |
| Biogen, INC. | $85.35 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $82.91 | 2022-2025 | Acessa Provu System, Novasure, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $62.19 | 2022-2024 | |
| Exact Sciences Corporation | $58.33 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $42.10 | 2023-2024 | Gardasil 9, Gardasil |
| Novo Nordisk INC | $38.15 | 2024 | Wegovy |
| Allergan, INC. | $34.20 | 2019-2020 | |
| Organon LLC | $33.41 | 2023-2025 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $31.71 | 2019 | |
| Duchesnay USA Incorporated | $28.81 | 2019 | |
| Therapeuticsmd, INC. | $28.36 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $22.04 | 2019 | |
| Ascend Therapeutics US, LLC | $16.50 | 2019 | |
| Kerecis Limited | $16.34 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Exeltis, USA INC. | $13.95 | 2025 | Slynd |
| Sanofi Pasteur INC. | $13.61 | 2025 | |
| Medtronic, INC. | $13.48 | 2025 | V-Loc 180 |
| Radius Health, INC. | $13.46 | 2024 | Tymlos |
| Pacira Pharmaceuticals Incorporated | $13.20 | 2023 | Exparel |
| Mission Pharmacal Company | $11.86 | 2019 | |
| Baxter Healthcare | $11.03 | 2019 | |
| Meditrina | $9.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Andersen-Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.